FDA Approves Capvaxive™: A Revolutionary Vaccine for Pneumonia and Invasive Disease
CAPVAXIVE (V116) is an FDA-approved vaccine for adults to combat invasive pneumococcal disease (IPD). It targets the serotypes responsible...
Pyros Pharmaceuticals’ FDA-Approved Vigafyde™: The Only Ready-to-Use Vigabatrin Oral Solution
Pyros Pharmaceuticals has received FDA approval for VIGAFYDE™, an oral vigabatrin solution for treating infantile spasms (IS) in pediatric...
PPD Receives CRO Leadership Award at 2024 DIA
PPD, a leader in clinical research, has received a CRO Leadership Award for the 13th consecutive year in recognition...
Unveiling the Promising Advancements in Blood Cancer Treatment: Innate Pharma’s Groundbreaking Trial Findings
At the European Hematology Association Congress, Innate Pharma and Sanofi presented promising results from their Phase 1/2 study of...
Empatica’s New Integration Enhances Clinical Mobility Solutions
Empatica, a leader in digital biomarker development, has partnered with Mobilise-D, an initiative funded by the Innovative Medicines Initiative....
Greenphire Launch of First Patient Data Set Paves Way for Clinical Trial Transformation
Greenphire unveils a groundbreaking Patient Experience Dataset, establishing the industry’s first repository of global patient-level insights. This dataset provides...
Calquence® Plus Chemoimmunotherapy: Remarkable Breakthrough in Mantle Cell Lymphoma Treatment
AstraZeneca’s CALQUENCE (acalabrutinib), combined with bendamustine and rituximab, has demonstrated significant benefits for patients with mantle cell lymphoma (MCL)....
Ensem Therapeutics Partners With Beigene as Novel CDK2 Inhibitor Enters Clinical Trials for Solid Tumors
Ensem Therapeutics has partnered with BeiGene to advance ETX-197, now known as BG-68501, into clinical trials. BG-68501 is a...
CyanVac Receives Barda-Funded Award to Evaluate Intranasal COVID-19 Vaccine Candidate in Phase 2b Study
CyanVac LLC, a biotechnology company, received federal funding to conduct a comparative Phase 2b study of CVXGA, its PIV5-based...
FDA Approves Augtyro™, a Next-Generation TKI for NTRK-Positive Tumors
The U.S. Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for treating patients aged 12 and older with...